Fund the plant, the clean rooms and the compliance behind them.
Term and working capital finance for formulation units, API and intermediate plants, nutraceutical and veterinary facilities — covering civil work, clean rooms, utilities, process equipment, validation and the working capital a regulated production cycle demands.
Compliance capex is most of the project
In pharmaceutical manufacturing, the regulated environment is the plant. Clean rooms to the required class, HVAC with defined air changes and pressure differentials, purified and water-for-injection systems, validated utilities, qualification and documentation — these routinely account for more of the project cost than the process machinery itself.
Revised Schedule M under the Drugs Rules raised the compliance bar for Indian manufacturers, with the government phasing implementation and extending timelines for smaller units subject to upgradation commitments. For a great many existing plants this means a mandatory capex cycle rather than an optional one, and lenders are actively funding these upgrades.
Validation and stability are cost and time, and both are frequently under-provided. Process validation batches, analytical method validation, equipment qualification and stability studies sit between mechanical completion and commercial production, and can add several months during which the plant consumes cash and produces nothing saleable. The moratorium has to cover that period, not just construction.
Indicative pricing in 2026
Pharma manufacturing attracts strong lender appetite and several government support schemes. Existing units with clean regulatory records price best.
Public Sector Banks
Tier-1 Private Banks
NBFCs & HFCs
Where pharma project files run short
Validation cost and time left out of the estimate
Mechanical completion is not commercial production. Qualification, process validation and stability studies stand between the two and consume months and cash. A project estimate that stops at commissioning under-funds the plant precisely when it has no revenue, and the shortfall is very hard to fill mid-project.
Schedule M upgradation treated as optional
Units that defer the upgrade risk their manufacturing licence, and lenders have become alert to this. A file from a plant with no credible upgradation plan carries a regulatory overhang. Conversely, a well-documented upgradation project is one of the easier pharma files to place at present.
Working capital sized for a shorter cycle than reality
Raw material and packaging procurement, in-process and finished-goods QC release, stability holds and then distributor credit produce a cash cycle commonly running 90–150 days. A limit sized on an optimistic cycle strains within two quarters. Model release timelines honestly.
Documents required
Incomplete files cause most multi-week delays. We assemble the full set upfront, in the order credit teams read it.
KYC & constitution
- PAN & Aadhaar of all promoters / partners / directors
- Certificate of incorporation, MOA-AOA or partnership deed
- Board resolution or partners' authority letter
- GST registration & trade licence
Regulatory & technical
- Manufacturing licence and product permissions from the state FDA
- GMP / WHO-GMP certificate and Schedule M compliance status
- Detailed project report with layout and clean-room classification
- Machinery quotations and utility specifications
- Pollution control board consent to establish and operate
- Fire NOC, factory licence and boiler approval where applicable
Financials
- 3 years audited financials with schedules
- 12 months' bank statements and GST returns
- Product-wise costing, margin and capacity utilisation projections
- Existing loan sanctions and repayment track
Related facilities & deep-dive guides
Every facility below is placed through the same 80+ lender panel. The long-form guides carry the working numbers, worked examples and lender-by-lender detail.
Frequently Asked Questions
The questions our advisory desk is asked most often about Pharma Manufacturing Loan.
Yes, and it is currently one of the more straightforward pharma files to place. Lenders understand the regulatory driver, and the project has a defined scope and outcome rather than resting on demand projections.
Bring the gap assessment, the upgradation plan, the layout drawings and the machinery and clean-room quotations. Where you own the plant, a mortgage on the property combined with a term loan is often the cheapest structure.
Long enough to reach commercial production, not just mechanical completion. That means construction, plus equipment installation and qualification, plus process validation and stability — commonly twelve to twenty-four months in total.
Projects that set the moratorium to the construction period alone find EMIs starting while validation batches are still running and no revenue exists. Negotiate this at sanction.
Several central and state schemes do, including support for common facilities and technology upgradation, alongside general MSME instruments such as CGTMSE cover and CLCSS subsidy where the unit qualifies.
Availability and terms change, so it is worth checking the current position through our government and PSU schemes desk before finalising the funding structure.
Plan for 90 to 150 days. Raw material and packaging procurement, in-process and finished-goods QC release, any stability hold, and then distributor credit all stack up.
Regulated-market exports typically run longer still. Size the cash credit limit on the honest cycle rather than the one that makes the file look tidy.
Yes, usually favourably. A loan-licence or contract manufacturing arrangement with an established brand owner gives the lender visible, contracted offtake instead of a demand projection.
Bring the manufacturing agreement, the volume commitments and the counterparty's profile. Concentration on a single principal will be noted, so multiple contracts read better than one.
Tell us what you need. We'll do the running around.
Share a few details and a CreditCares expert will call you back to map your eligibility and shortlist the right lenders — at no cost.